- Title: Subtitle
- Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)
- Creators
- Robert J. Hopkin - Cincinnati Children's Hospital Medical CenterJaya Ganesh - Icahn School of Medicine at Mount SinaiJohn Bernat - University of IowaOzlem Goker-Alpan - Lysosomal and Rare Disorders Research and Treatment CenterKathleen Nicholls - Royal Melbourne HospitalMadeleine V. Pahl - University of California, IrvinePatrick B. Deegan - Addenbrooke's HospitalChester B. Whitley - University of MinnesotaDerralynn Hughes - The Royal Free HospitalLiching Cao - Sangamo BioSciencesMichael Chen - Sangamo BioSciencesLisa Shiue - Sangamo BioSciencesLisa Rojkjaer - Sangamo BioSciencesWilliam R. Wilcox - Emory University School of Medicine
- Resource Type
- Abstract
- Publication Details
- Molecular genetics and metabolism, Vol.141(2), 107884
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.ymgme.2023.107884
- ISSN
- 1096-7192
- eISSN
- 1096-7206
- Language
- English
- Date published
- 02/2024
- Academic Unit
- Stead Family Department of Pediatrics; Medical Genetics and Genomics
- Record Identifier
- 9984557959402771
Abstract
Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)
Molecular genetics and metabolism, Vol.141(2), 107884
02/2024
DOI: 10.1016/j.ymgme.2023.107884
Details
Metrics
10 Record Views